Single-Dose Sufentanil NanoTab: Phase III started

AcelRx began the double-blind, placebo-controlled, U.S. Phase III SAP301 trial to evaluate 30 ug sublingual ARX-04 given by a healthcare professional no more than once per hour for up to 48 hours in a...